Cyrus Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cyrus Therapeutics, Inc. - overview
Established
2019
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2019 by Byong-Moon Kim (CEO), Cyrus Therapeutics, Inc. operates as a biotechnology company specializing in developing a new anticancer drug for a resistance-causing target. In January 2022, Cyrus Therapeutics, Inc. raised KRW 29 billion in series C funding from Kolon Investment, Paratus Investment, Timefolio Asset Management, Atinum Investment, etc.
Cyrus Therapeutics, Inc. provides medicine developers focusing on chronic or life-threatening diseases with high unmet needs. Furthermore, the company's technology employs a variety of new drug modalities, including traditional small molecule inhibitors and the primary focus is on developing small molecule medicines to conquer unsolvable cancer targets, as well as expanding new chemical spaces such as targeted protein degraders (TPDs) and antibody recruiting molecules (ARMs). The investment which was held on January 2022, plans to help Cyrus Therapeutics, Inc.
in its pipeline development-related clinical trials and secure additional pre-clinical tasks by next year.
Current Investors
Timefolio Asset Management, Kolon Investment, Paratus Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.cyrustx.com
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.